|
Antibioticsa
|
Number of the 1472 study women who were colonized with resistant bacteria (prevalence of colonization/proportion of isolates, in %)
|
|---|
|
E. coli (n = 504/508)c
|
K. pneumoniae (n = 144/145)
|
Enterobacter spp. (n = 32/32)
|
K. oxytoca (n = 23/23)
|
Citrobacter spp. (n = 107/107)
|
Acinetobacter spp. (n = 32/32)
|
Pseudomonas spp. (n = 3/3)
|
Proteus spp. (n = 3/3)
|
|---|
|
Ampicillin
|
454 (30.8/89.4)
|
141 (9.6/97.2)
|
31 (2.1/96.9)
|
22 (1.5/95.7)
|
105 (7.1/98.1)
|
NA
|
0 [6]
|
1 (0.1/33.3)
|
|
Amoxycillin-Clavulanic acid
|
366 (24.9/72.0)
|
120 (8.2/82.8)
|
31 (2.1/96.9)
|
14 (0.9/60.9)
|
80 (5.4/74.8)
|
NA
|
NA
|
1 (0.1/33.3)
|
|
Trimethoprim-Sulfamethoxazole
|
354 (24.0/69.7)
|
90 (6.1/62.1)
|
17 (1.2/53.1)
|
9 (0.6/39.1)
|
56 (3.8/52.3)
|
21 (1.4/65.6)
|
NA
|
0 [6]
|
|
Ciprofloxacin
|
74 (5.0/14.6)
|
26 (1.8/17.9)
|
3 (0.2/9.4)
|
1 (0.1/4.3)
|
18 (1.2/16.8)
|
9 (0.6/28.1)
|
0 [6]
|
0 [6]
|
|
Chloramphenicol
|
103 (7.0/20.3)
|
36 (2.4/24.8)
|
5 (0.3/15.6)
|
4 (0.3/17.4)
|
18 (1.2/16.8)
|
4 (0.3/12.5)
|
0 [6]
|
0 [6]
|
|
Gentamicin
|
111 (7.5/21.9)
|
37 (2.5/25.5)
|
6 (0.4/18.8)
|
3 (0.2/13.0)
|
22 (1.5/20.6)
|
7 (0.5/21.9)
|
1 (0.1/33.3)
|
0 [6]
|
|
Amikacin
|
125 (8.5/24.6)
|
33 (2.2/22.8)
|
9 (0.6/28.1)
|
2 (0.1/8.7)
|
19 (1.3/17.8)
|
6 (0.4/18.8)
|
0 [6]
|
0 [6]
|
|
Ceftriaxone
|
92 (6.3/18.1)
|
42 (2.9/29.0)
|
4 (0.3/12.5)
|
4 (0.3/17.4)
|
31 (2.1/29.0)
|
NA
|
NA
|
0 [6]
|
|
Cefuroxime
|
366 (24.9/72.0)
|
92 (6.3/63.4)
|
28 (1.9/87.5)
|
8 (0.5/34.8)
|
83 (5.6/77.6)
|
NA
|
NA
|
1 (0.1/33.3)
|
|
Ceftazidime
|
55 (3.7/10.8)
|
30 (2.0/20.7)
|
1 (0.1/3.1)
|
3 (0.2/13.0)
|
7 (0.5/6.5)
|
13 (0.9/40.6)
|
0 [6]
|
0 [6]
|
|
Imipenem
|
41 (2.8/8.1)
|
19 (1.3/13.1)
|
9 (0.6/28.1)
|
1 (0.1/4.3)
|
27 (1.8/25.2)
|
2 (0.1/6.3)
|
0 [6]
|
0 [6]
|
|
Tetracycline
|
NA
|
NA
|
NA
|
NA
|
NA
|
9 (0.6/28.1)
|
0 [6]
|
NA
|
|
Piperacillin
|
NA
|
NA
|
NA
|
NA
|
NA
|
16 (1.1/50.0)
|
0 [6]
|
NA
|
|
Piperacillin-Tazobactam
|
NA
|
NA
|
NA
|
NA
|
NA
|
11 (0.7/34.4)
|
0 [6]
|
NA
|
|
Colistin
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
0 [6]
|
NA
|
|
ESBL-producing bacteria
|
36 (2.4/7.1)
|
16 (1.1/11.0)
|
1 (0.1/3.1)
|
1 (0.1/4.3)
|
3 (0.2/2.8)
|
NA
|
NA
|
0 [6]
|
|
Carbapenem-resistant bacteria
|
41 (2.8/8.1)
|
19 (1.3/13.1)
|
9 (0.6/28.1)
|
1 (0.1/4.3)
|
27 (1.8/25.2)
|
2 (0.1/6.3)
|
0 [6]
|
0 [6]
|
|
MDR
|
426 (28.9/83.9)
|
89 (6.0/61.4)
|
22 (1.5/68.8)
|
6 (0.4/26.1)
|
62 (4.2/57.9)
|
18 (1.2/56.3)
|
2 (0.1/66.7)
|
1 (0.1/33.3)
|
|
MDRb
|
350 (23.8/68.9)
|
54 (3.7/37.2)
|
12 (0.8/37.5)
|
4 (0.3/17.4)
|
32 (2.2/29.9)
|
18 (1.2/56.3)
|
2 (0.1/66.7)
|
1 (0.1/33.3)
|
- aNA indicates that the antibiotic was not tested or was not relevant for the given organism
- bMDR excluding ESBL-producing and carbapenem-resistant bacteria
- cThe two numbers in parentheses indicate number of colonized women and the number of isolates of each given species, respectively
